RVX vs. HBP, SCYB, COM, NVH, IGX, MDNA, PDP, COV, SVA, and EMH
Should you be buying Resverlogix stock or one of its competitors? The main competitors of Resverlogix include Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), IntelGenx Technologies (IGX), Medicenna Therapeutics (MDNA), Pediapharm (PDP), Covalon Technologies (COV), Sernova (SVA), and Emerald Health Therapeutics (EMH). These companies are all part of the "biotechnology" industry.
Resverlogix vs. Its Competitors
Helix BioPharma (TSE:HBP) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.
Resverlogix is trading at a lower price-to-earnings ratio than Helix BioPharma, indicating that it is currently the more affordable of the two stocks.
In the previous week, Helix BioPharma had 4 more articles in the media than Resverlogix. MarketBeat recorded 4 mentions for Helix BioPharma and 0 mentions for Resverlogix. Helix BioPharma's average media sentiment score of 0.19 beat Resverlogix's score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.
Helix BioPharma has a beta of -0.449843, indicating that its share price is 145% less volatile than the S&P 500. Comparatively, Resverlogix has a beta of 1.154049, indicating that its share price is 15% more volatile than the S&P 500.
0.0% of Helix BioPharma shares are held by institutional investors. Comparatively, 0.0% of Resverlogix shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by company insiders. Comparatively, 42.7% of Resverlogix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Helix BioPharma's return on equity of 1,803.57% beat Resverlogix's return on equity.
Summary
Resverlogix beats Helix BioPharma on 6 of the 10 factors compared between the two stocks.
Get Resverlogix News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Resverlogix Competitors List
Related Companies and Tools
This page (TSE:RVX) was last updated on 9/13/2025 by MarketBeat.com Staff
